Mayne Pharma has rejected Cosette Pharmaceuticals’ attempt to terminate their scheme implementation deed (SID), asserting that the termination notice is

Formation Bio has entered a landmark agreement with Lynk Pharmaceuticals to acquire worldwide rights (excluding Greater China) to LNK01006, a next-generation,

Teva Pharmaceuticals has agreed to delist more than 200 patents from the FDA’s Orange Book, a move the Federal Trade Commission (FTC) is calling a major win

The U.S. Food and Drug Administration (FDA) has released final guidance detailing the requirements for promotional labeling and advertising of biosimilars,

Scientists are preparing to launch clinical trials for antibodies that were designed from scratch by artificial intelligence, marking a significant turning

French biotechnology company Abivax experienced a dramatic rise in its stock price on December 10, 2025, with shares jumping over 20% amid rumors that Eli

Pfizer has announced a significant expansion of its obesity drug portfolio with a $1.9 billion licensing deal for Yao Pharma’s oral GLP-1 receptor agonist

GSK has moved to discontinue its long‑running synthetic lethality collaboration with Ideaya Biosciences, formally giving notice that it will terminate the

Dr. Reddy’s Laboratories has signed a major oncology licensing deal for eftilagimod alfa (efti), Immutep’s lead LAG‑3–based immunotherapy, in an agreement

SeaBeLife, a French biotech focused on cellular necrosis, has announced a joint development agreement with Unither Pharmaceuticals to advance its lead drug

Wave Life Sciences and Structure Therapeutics both experienced dramatic stock surges after releasing new clinical data for their respective obesity drug

Mirum Pharmaceuticals has struck a deal to buy Bluejay Therapeutics, a private biotech focused on viral and liver diseases, in a transaction valued at $620

Innovent Biologics has confirmed that its global strategic partnership with Takeda has closed and become effective, following satisfaction of all closing

AstraZeneca has returned to Neurimmune for a second amyloidosis asset, signing a licensing pact for the preclinical monoclonal antibody NI009 in light chain

Paradigm Health has raised $78 million in a Series B round to scale its technology-first approach to clinical research and redefine how trials are run. The

Pharvaris, the Netherlands-based biotech, has delivered promising topline results from its RAPIDe-3 Phase 3 trial evaluating deucrictibant as an oral

Medtronic has announced that its Hugo Robotic-Assisted Surgery (RAS) System has received FDA clearance for use in the United States, enabling the company to

Triana Biomedicines has successfully closed a $120 million Series B financing to propel its pioneering glue degrader platform into the clinic. The round is

Avetra has emerged as a new “next-generation” CRO with a mission to overhaul how clinical trials are run by centering its model around investigative sites

Lantern Pharma, an AI-driven oncology company, is advancing its investigational cancer drug LP-184 after reporting a successful Phase 1a trial in patients

Excelsior Sciences has emerged from stealth with $95 million in fresh capital to re-engineer how small-molecule drugs are invented and manufactured. The

Axoltis Pharma, a French biotech focused on neurodegenerative and neurotraumatic diseases, has raised €18 million in a Series A financing to speed up

Roche has secured regulatory green lights on both sides of the Atlantic for its first point-of-care test for whooping cough, as health systems grapple with a

Akebia Therapeutics has struck a deal to acquire rights to Q32 Bio’s rare kidney disease candidate ADX‑097, committing $12 million in upfront payments as it

Regeneron Pharmaceuticals has entered a global collaboration with Tessera Therapeutics to develop and commercialize TSRA-196, an investigational in vivo gene

U.S. President Donald Trump has announced a new trade agreement with Britain that will set tariffs on UK pharmaceuticals and medical technologies exported to

With an oversubscribed $130 million Series B round, Protego Biopharma is advancing a first-in-class oral therapy that targets the root cause of AL (amyloid

Hologic, Inc. | 282,889 followers on LinkedIn. The Science of Sure | We’re an innovative medical technology company whose purpose is to enable healthier lives everywhere, every day. While we discover...

Almac Group has announced a multi-million-pound investment to expand its facility in Singapore, coinciding with the company’s tenth anniversary of operations

Biogen has announced a research collaboration with Dayra Therapeutics, a new biotech launched by Versant Ventures, to discover and develop oral macrocyclic

Moderna, the U.S.-based biotechnology company, has announced a significant new manufacturing partnership in China, formalizing its first major investment in

eXmoor Pharma, an integrated cell and gene therapy contract development and manufacturing organisation (CDMO), and Royal Free London NHS Foundation Trust have

Medicare has announced substantial price reductions for 15 widely used prescription drugs, marking the second major round of negotiations under the Inflation

Otsuka Pharmaceutical achieved a significant regulatory milestone on November 25, 2025, when the U.S. Food and Drug Administration granted accelerated

French pharmaceutical giant Sanofi faced heightened regulatory scrutiny on November 25, 2025, when approximately 30 judicial tax officers from the National

Valneva, a specialty vaccine company, announced on November 26, 2025, a significant organizational restructuring involving the closure of its Nantes facility

Novartis announced the FDA approval of Itvisma, a novel gene replacement therapy designed for individuals living with spinal muscular atrophy (SMA) aged two

Moderna, Inc. announced it has secured a five-year, $1.5 billion debt facility with Ares Management Credit Funds to fund its growth and provide financial

Aspen Neuroscience, a clinical-stage biotech pioneer in personalized regenerative therapies, announced the successful close of a $115 million Series C funding

Alkermes has significantly escalated its pursuit of Avadel Pharmaceuticals , a biotech company specializing in treatments for sleep disorders, by raising its

Novo Nordisk , the Danish pharmaceutical company known for blockbuster diabetes and obesity treatments Ozempic and Wegovy, disclosed top-line results from its

Regeneron Pharmaceuticals secured two significant FDA approvals for its high-dose Eylea (8 mg aflibercept), a key drug for serious eye diseases. The first

Moderna, the Massachusetts-based biotech pioneer known for its COVID-19 mRNA vaccines, is significantly bolstering its U.S. manufacturing footprint with a

Roche has deepened its bet on blood-based cancer screening by signing a broad licensing and collaboration agreement with Freenome, a California-based

Avadel Pharmaceuticals finds itself in a heated acquisition contest as two prominent players vie for control of the sleep-focused biotech. Alkermes initially

Medicxi has closed its largest investment vehicle to date, €500 million Fund V, marking a significant milestone in the firm’s commitment to fostering

Abbott Laboratories is making a landmark push into cancer diagnostics with its agreement to acquire Exact Sciences for roughly $23 billion, including $21

Precise Bio, a clinical-stage regenerative medicine company specializing in 3D bioprinted tissues, announced the successful implantation of PB-001, the

South Korean biopharmaceutical giant Celltrion announced a major strategic deal with Korea-based TriOar Therapeutics, acquiring an option to license the